Rezubio doses first cohort in Phase I trial of inhaled RZ-520

Rezubio has dosed the first cohort of patients in a Phase I trial of RZ-520, an inhaled therapeutic drug for chronic respiratory diseases. The trial is assessing the tolerability, safety, pharmacodynamics and pharmacokinetics in healthy volunteers. RZ-520 is designed to maintain drug exposure within the lung. Credit: sasirin pamai / Shutterstock.com. Rezubio has dosed the first cohort of patients in a Phase I trial of RZ-520, an inhaled therapeutic drug for chronic respiratory diseases. The study follows investigational new drug clearances (IND) from China’s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). LOA and PTSR…

Source: Clinical Trials Arena